Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06737848

The Comparison of Single Catheter and Double Catheter Adrenal Vein Sampling Methods Based on the Upper Limb Approach

Primary Aldosteronism (PA) is a clinical syndrome characterized by the autonomous overproduction of aldosterone by the adrenal cortex's zona glomerulosa, leading to hypertension, elevated aldosterone levels, and suppressed renin activity as the primary manifestations. Studies have shown that the prevalence of PA in an unselected hypertensive population ranges from 5% to 11% , while the prevalence in patients with resistant hypertension is approximately 20% . PA is one of the most common causes of secondary hypertension , and its prevalence increases with rising blood pressure levels. Due to the adverse effects of PA on the heart, arterial walls, and kidneys, it contributes to the occurrence of cardiovascular events, with atrial fibrillation being the most common . In summary, PA is characterized by rapid onset, significant symptoms, obscurity, and severe complications, making early diagnosis and targeted treatment essential for prevention.

This study aims to explore a quasi-selected prospective randomized controlled method to compare the clinical efficacy differences between single-catheter and dual-catheter adrenal sampling via the right upper limb approach. The study seeks to clarify the effectiveness and safety of single-catheter sampling from the upper limb, providing a more efficient and cost-effective solution for the subtype diagnosis of patients with Primary Aldosteronism (PA).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18-70 years with hypertension.
  • Initial screening shows a standing aldosterone/renin ratio (ARR) > 3.7, a baseline aldosterone level > 10 ng/dl, aldosterone level > 6 ng/dl after a saline load test, or aldosterone decrease of less than 30% after a captopril suppression test, consistent with a diagnosis of primary aldosteronism.
  • Voluntary participation in the trial, with signed informed consent.

Exclusion criteria

  • Patients with an allergy to iodinated contrast agents.
  • Patients who are pregnant, breastfeeding, or planning to become pregnant.
  • Patients with severe comorbidities, such as renal failure, liver cirrhosis, metastatic tumors, or those who have had an acute stroke or acute myocardial infarction, as well as patients with a history of surgery within the past month.
  • Patients suspected of having adrenal cortical carcinoma.

Treatment and study plan

Single catheter adrenal vein sampling

Procedure

The clinical invasive procedure involves inserting a single catheter into the right and left adrenal veins to collect blood samples from both adrenal veins.

Double catheters adrenal vein sampling

Procedure

The clinical invasive procedure involves inserting double catheters into the right and left adrenal veins to collect blood samples from both adrenal veins.

Primary outcomes

  1. Success rate of left-sided adrenal vein sampling between two groups

    Time frame: 7 month(End of Trial)

    Biochemical analysis of puncture-point blood samples: A selection index (SI) ≥ 2, defined as the ratio of adrenal plasma cortisol concentration (PCC) to peripheral PCC, indicates successful unilateral aldosterone venous sampling (AVS).

Secondary outcomes

  1. Change of material costs between two groups

    Time frame: 7 month(End of Trial)

  2. Change of average operation time of left-side adrenal vein sampling between two groups

    Time frame: 7 month(End of Trial)

    The surgical doctor will record the operation time for adrenal vein sampling from the left adrenal vein and compare change of the average operation time between the two groups at end of the study.

  3. Change of average fluoroscopy time of adrenal vein sampling between two groups

    Time frame: 7 month(End of Trial)

    Change of average fluoroscopy time of adrenal vein sampling between two groups at the end of the study.

  4. Change of the surgical supplies cost between two groups

    Time frame: 7 month(End of Trial)

    Change of the surgical supplies cost between two groups at the end of the study.

Study contacts

Contact information is provided by the study sponsor or research team.

Li Li,MD

CONTACT

[email protected]

13372683559

Sponsors and collaborators

Lead sponsor

Army Medical University, China

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Dec 17, 2024
Registry last updated
Dec 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.